Sugi Predict

Sugi Predict / Compounds / SCHEMBL4170248

SCHEMBL4170248

SCHEMBL4170248

CN(C)C1CCN(c2cccc(-c3cn[nH]c3N)c2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.43
▸ TIPARP Q7Z3E1 1/20 0.40
▸ PTPN11 Q06124 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ HTR7 P34969 2/20 0.39
▸ HTR1A P08908 1/20 0.38
▸ PIK3CD O00329 1/20 0.38
▸ DHFR P00374 1/20 0.38
▸ ADORA2A P29274 1/20 0.37
▸ PDCD1 Q15116 1/20 0.37
▸ CD274 Q9NZQ7 1/20 0.37
▸ CDK1 P06493 1/20 0.37
▸ CDK4 P11802 1/20 0.37
▸ CCNB1 P14635 1/20 0.37
▸ CCND1 P24385 1/20 0.37
▸ CCND3 P30281 1/20 0.37
▸ CDK6 Q00534 1/20 0.37
▸ VCP P55072 1/20 0.37
▸ MAPT P10636 2/20 0.36
▸ GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3580409 0.82 ADRA2C (0.54) LMNAKDM4EHTR7HTR1AMAPT
SCHEMBL4754710 0.80 LMNA (0.50) LMNAKDM4EHTR7HTR1ADHFR
SCHEMBL4171391 0.79 LMNA (0.49) LMNADHFR
SCHEMBL4170081 0.79 ALDH1A1 (0.51) LMNAVCP
SCHEMBL4176127 0.76 LMNA (0.46) LMNAKDM4EADORA2AMAPTGAA
SCHEMBL5743091 0.76 LMNA (0.46) LMNAKDM4EADORA2AMAPTGAA
SCHEMBL4167689 0.75 LMNA (0.48) LMNAKDM4EDHFR
SCHEMBL3440424 0.75 ADRA2C (0.57) LMNAPTPN11KDM4EPDCD1CD274
SCHEMBL17754015 0.70 ADRB1 (0.56) HTR7DHFRMAPTNSD2SETD2
SCHEMBL2174889 0.69 NPY5R (0.53) HTR7DHFRNSD2SETD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099167-A1 Organic compounds NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH 2009-04-16 — — US disclosed
US-20090069315-A1 Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders SIVASANKARAN RAJEEV 2009-03-12 — — US disclosed
EP-1708710-A1 PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2006-10-11 — — EP disclosed
US-20050222171-A1 Organic compounds NOVARTIS AG (CH) 2005-10-06 — — US disclosed
WO-2005070431-A1 PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2005-08-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069315-A1 Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders EPHA5, EPHA7, EPHA1 LMNA 4109/4885TIPARP 1886/4885PTPN11 1588/4885
US-20050222171-A1 Organic compounds JAK1, MAP3K5, MAP3K7 LMNA 2478/4885TIPARP 2784/4885PTPN11 1172/4885
US-20090099167-A1 Organic compounds JAK1, MAP3K5, MAP3K7 LMNA 2478/4885TIPARP 2784/4885PTPN11 1172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.